The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
BUSINESS
Amicus CEO Confident on US$1 Billion Sales Target as Japan Pompe Launch Gets Underway
As Amicus Therapeutics celebrates the Japan debut of its Pompe disease therapy, President and CEO Bradley Campbell expressed confidence that the US biotech is on track to reach US$600 million in global revenue for FY2025, up more than 10% over…
To read the full story
Related Article
- Amicus’ Pompe Disease Drugs Hit Japan Market
August 28, 2025
- Amicus to Enroll PIII Study for Pompe Therapy AT-GAA by Year-End: COO
June 10, 2019
BUSINESS
- Mochida’s EPA Drug Epadel S Wins Approval in China
January 9, 2026
- Keytruda Tops Japan Drug Sales Again in December, Marking 27-Month Run: Encise
January 9, 2026
- Hisamitsu to Go Private in Management Buyout Valued at 400 Billion Yen
January 8, 2026
- AbbVie Introduces No-Relocation Work Option for Sales Staff
January 8, 2026
- Generic Makers Positive on New AG Pricing, Cite Gains in Productivity and Predictability
January 8, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…